PUBLISHER: IMARC | PRODUCT CODE: 2032594
PUBLISHER: IMARC | PRODUCT CODE: 2032594
The global EPA & DHA market size reached USD 2,104.4 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 3,455.5 Million by 2034, exhibiting a growth rate (CAGR) of 5.50% during 2026-2034. The increasing consumer awareness about the health benefits of omega-3 fatty acids, rising demand for functional foods and supplements, and the growing prevalence of sustainable and eco-friendly sourcing practices in the fishing industry represent some of the key factors driving the market.
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) refer to long-chain polyunsaturated omega-3 fatty acids with similar chemical structures that are essential for human health. Usually found in fatty fish, such as salmon, mackerel, sardines and algae, EPA and DHA are not synthesized by the human body and must be obtained through diet or supplementation. EPA and DHA from fish and supplements are highly bioavailable, therefore they are absorbed by the human body relatively easily and can be incorporated into cell membranes and other structures where they are needed. EPA and DHA are important for brain function and development as they protect against cognitive decline and their anti-inflammatory properties help to reduce the risk of chronic diseases, such as heart disease, cholesterol, and arthritis. In addition to this, EPA and DHA are important for regulating the immune system, benefitting skin health and minimizing the risks of age-related macular degeneration.
The global market is majorly driven by the augmenting demand for supplements and functional foods containing EPA and DHA. This can be attributed to the rising incidences of chronic diseases, such as heart disease, diabetes, and cancer among the masses, particularly the geriatric population. In line with this, the increasing awareness among consumers regarding health and fitness is also propelling the demand for EPA and DHA fortified foods. Moreover, the increasing usage of EPA and DHA in infant formula and pet food is creating lucrative growth opportunities in the market. Besides this, continual technological advancements in the processing techniques enabling manufacturers to produce high-purity and high-concentration EPA and DHA supplements and functional foods are providing an impetus to the market. The growing adoption of plant-based vegan diets among the consumer base is resulting in a higher uptake of plant-based sources of EPA and DHA, such as algae-based supplements and foods. The market is further fueled by the paradigm shift in regulations and labeling requirements for food and supplements, resulting in companies adjusting their formulations and marketing strategies to comply with new rules. Some of the other factors contributing to the market include rapid urbanization, growing prevalence of sustainable and eco-friendly sourcing practices in the fishing industry, inflating disposable income levels, and extensive research and development (R&D) activities conducted by the key players.
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific was the largest market for EPA & DHA. Some of the factors driving the Asia Pacific EPA & DHA market included the growing geriatric population, continual technological advancements in sustainable fishing practices, increasing awareness regarding health and fitness, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global EPA & DHA market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AlgiSy BioSciences Inc., Arctic Nutrition AG, BASF SE, Biosearch Sau, Corbion NV, Croda International PLC, KD Pharma Group, Koninklijke DSM NV, Nordic Naturals Inc, Novasep Holding SAS, Novotech Nutraceuticals Inc, Omega Protein Corporation, Polaris, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.